The Alzheimer's Disease Symposium, co-sponsored by Shenzhen Medical Academy of Research and Translation (SMART) and Shenzhen Bay Laboratory (SZBL), was held in Guangming, Shenzhen on 22 September, kicking off the SMART Symposium Academic Conference Series in the second half of 2024, with more than 40 top experts and numerous researchers from all over the world coming to Shenzhen to participate in this important academic event. After several exciting presentations and lively exchanges and discussions, the symposium came to a successful conclusion on 24 September.
The symposium was co-sponsored by Guo Tengfei, a researcher at the Shenzhen Bay Laboratory, together with Professor William Jagust of UC Berkely, Professor Michael Weiner of UCSF, Professor Han Ying of Xuanwu Hospital of Capital Medical University, Researcher Xie Fang of Huashan Hospital of Fudan University, and Professor Ye Keqiang of Shenzhen University of Science and Technology. It focuses on the early recognition and effective intervention of Alzheimer's disease, aiming to enhance public and professional awareness and understanding of this disease.
Experts shared the latest research progress in the early diagnosis and treatment of Alzheimer's disease, including the discovery of APOE risk genes and biomarkers, the application of imaging techniques, and the importance of multidisciplinary cooperation in clinical practice. The organizing committee also set up a special session for young scholars, inspiring them to show the vitality and hope of the academic community. All participants discussed the research, early diagnosis and intervention of Alzheimer's disease cohorts at home and abroad, and delved into the use of emerging technologies and methods to achieve early screening and personalized treatment.
Professor Leslie M. Shaw, Chief Scientist, Centre for Body Fluid Markers, ADNI Database (Alzheimer's Disease Neuroimaging Initiative) and University of Pennsylvania, shared online the most valuable plasma p-tau217 biomarker for early diagnosis. tau217 biomarker, suggesting a pathway for wider implementation in the future.
Professor Colin Masters from the University of Melbourne, the founder of the AIBL cohort and one of the key discoverers of Aβ1-42, shared his research and understanding of Alzheimer's disease pathology, early diagnosis and intervention; and Professor Michael Weiner, Chief Scientist of the ADNI cohort and the Chief Scientist of the ADNI database at the University of California San Francisco (UCSF), talked about the different stages of development and representative studies of the ADNI database. Professor Michael Weiner talked about the different stages of development and representative studies of the ADNI database.
Professor William Jagust, Chief Scientist of the PET Centre of the ADNI Database, University of California, Berkeley (UC Berkeley), shared his experience and the latest advances in neuroimaging for Alzheimer's disease; Professor Clifford Jack, Chief Scientist of the MRI Centre of the ADNI Database, Mayo Clinic, talked about the latest diagnostic criteria for Alzheimer's disease. Professor Clifford Jack, Chief Scientist, MRI Centre, ADNI Database, Mayo Clinic, talked about the latest diagnostic criteria for Alzheimer's disease - he is the initiator of the NIA-AA International Diagnostic Criteria for Alzheimer's Disease in 2018 and 2024, and the author of the Jack Curve for AD Evolutionary Trajectories.
In addition, experts in Alzheimer's disease risk gene APOE research, Professor Bu Guojun of the Hong Kong University of Science and Technology and Professor Huang Yadong of UCSF shared the progress related to the early diagnosis and treatment of Alzheimer's disease around the APOE risk gene one after another, and Professor Karen Ashe of the University of Minnesota shared the latest findings of the impact of tau protein cleavage on a variety of dementia pathologies, and discussed the prospects of Caspase- 2 inhibitors to improve the therapeutic prospects of memory.
Other researchers in the field also shared the latest research progress related to early diagnosis and treatment, mainly based on the latest development of early diagnostic technologies such as digital markers, ocular imaging technologies, humoral biomarkers, risk genes, MRI and PET imaging, etc. A series of discussions were held on Alzheimer's disease cohort building, early diagnostic technologies and intervention strategies.
The symposium also set up a special session for young people. Young scholars from Central South University, Shanghai Jiao Tong University, Zhejiang University, Fujian Medical University, Capital Medical University, Peking University Shenzhen Hospital, Beijing Normal University, University of Tokyo, and Shenzhen Bay Laboratory shared their latest progress, all of which were commented on by experts from home and abroad, and engaged in fascinating discussions with the attendees.
This symposium is modeled after the conference format of the Alzheimer's Association International Conference (AAIC), with ample discussion sessions and top experts in both clinical and basic research fields, allowing participants to experience SMART Symposia as a highly international academic platform where researchers can fully enjoy the exciting academic discussions and young scholars have ample opportunities [1] to get guidance and advice from senior researchers. Scholars from all over the world share successful cases and practical experiences, providing valuable knowledge and inspiration and promoting international cooperation and innovation. This symposium promotes academic communication between basic researchers and clinicians in the field of Alzheimer's disease and is expected to promote the establishment of closer cooperation between domestic and foreign researchers in the early diagnosis and treatment of Alzheimer's disease.
Source: SMART International Exchange Center
Executive Editor: Winston
Editor: Bai Bai
For more information, please contact media@szbl.ac.cn
